AARD
Aardvark Therapeutics, Inc. Common Stock
NASDAQ: AARD · HEALTHCARE · BIOTECHNOLOGY
$5.21
-6.80% today
Updated 2026-04-29
Market cap
$113.66M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-2.93
Dividend yield
—
52W range
$3 – $18
Volume
0.3M
Aardvark Therapeutics, Inc. Common Stock (AARD) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — |
| Cost of revenue | $110000.00 | $97000.00 | $16000.00 | $36000.00 |
| Gross profit | $-110000.00 | $-97000.00 | $-16000.00 | $-36000.00 |
| Gross margin | — | — | — | — |
| R&D | $7.17M | $4.48M | $17.36M | $48.94M |
| SG&A | $2.70M | $2.17M | $5.30M | $13.79M |
| Operating income | $-11.36M | $-7.42M | $-22.79M | $-62.73M |
| Operating margin | — | — | — | — |
| EBITDA | $-9.76M | $-6.65M | $-22.65M | $-62.73M |
| EBITDA margin | — | — | — | — |
| EBIT | $-9.87M | $-7.42M | $-22.67M | — |
| Interest expense | — | — | — | — |
| Income tax | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-13.56M | $-7.21M | $-20.59M | $-57.59M |
| Net income growth (YoY) | — | +46.9% | -185.6% | -179.7% |
| Profit margin | — | — | — | — |